In a rare case of the sharemarket mirroring life, a COVID-19-induced Chinese takeaway has turned into a real dog's breakfast.
Our cautionary tale starts when hair-loss treatment company Cellmid announced it had raised more than $6 million to buy point-of-care (PoCT) COVID-19 antibody tests from Chinese company Wondfo.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
